The introduction of MenAfriVac in 2010 was viewed as a big event at the time. Its story of a nonprofit stepping into the domain of Big Pharma and developing a meningitis vaccine gained international news coverage. Until this week though, nobody knew the full significance of that 2010 launch.
The FDA is not alone in cracking down on drug compounders. State authorities in Massachusetts have been taking action after being caught off-guard last year when a nationwide, fatal meningitis outbreak was tied to a compounder there. It recently ordered operations halted at two compounders.
The recent outbreak of bacterial meningitis among gay and bisexual men in New York City raised fears of an AIDS-like epidemic. Things are different this time though. Health authorities have a vaccine to hold back the spread of the disease.
Novartis' Bexsero may be the only vaccine approved for life-threatening meningitis B, but that wasn't enough to convince the U.K.'s Joint Committee on Vaccination and Immunisation to add it to Britain's routine vaccination schedule.
The obstacles to increasing rates of immunization include social, political and economic factors as well as failings of the healthcare infrastructure itself. With a meningitis outbreak spreading across New York City, lawmakers are trying to remove one such obstacle.
In the first 5 months of 2013, 857 deaths were reported in countries under enhanced surveillance.
Novartis nabbed EU approval of Bexsero, a meningitis B vaccine the company has been banking on to bolster its lagging vaccine unit.
Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.
Novartis ($NVS) nabbed European approval for its new meningitis B vaccine Bexsero, for use in patients 2 months of age and older.
Novartis, still riding high on a European Medicine Agency committee backing of its meningitis vaccine Bexsero, confirmed more upbeat results from a study showing the shot offered broad protection to infants.